Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Atsena's gene therapy readout illuminates eye disease efficacy
Atsena is forging ahead with a study that could support a filing for approval in 2028.
Nick Paul Taylor
Oct 7, 2026 9:09am
ArriVent’s phase 3 lung cancer trial flops, sinking stock
Oct 6, 2026 10:51am
Kairos seizes moment to push cancer asset into earlier setting
Oct 6, 2026 8:58am
Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere
Oct 5, 2026 4:14am
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose
Sep 30, 2026 4:57am
uniQure stock crashes as Huntington’s gene therapy data weaken
Sep 29, 2026 9:28am
